M.D. Anderson to Hold Conference in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

HOUSTON--The University of Texas M.D. Anderson Cancer Center will hold its second medical oncology conference in Spanish on May 22-24, 1996. The educational conference will bring together physicians from Spain and Latin American with the M.D. Anderson faculty, said Richard Pazdur, MD, associate professor of medicine and co-director of the conference along with Alejandro Preti, MD, assistant professor of medicine.

HOUSTON--The University of Texas M.D. Anderson Cancer Center willhold its second medical oncology conference in Spanish on May22-24, 1996. The educational conference will bring together physiciansfrom Spain and Latin American with the M.D. Anderson faculty,said Richard Pazdur, MD, associate professor of medicine and co-directorof the conference along with Alejandro Preti, MD, assistant professorof medicine.

"I think M.D. Anderson is unique in that it has such a diversegroup of Spanish-speaking faculty, both native speakers and thosewho learned the language along the way," Dr. Pazdur saidin an interview. Most of the speakers are M.D. Anderson faculty.In addition, physicians from Spain have been invited to discusstheir research work at a symposium to be held in conjunction withthe conference.

ASCO Findings Will Be Reviewed

The meeting will also provide an opportunity for a discussionof studies presented at the 1996 American Society of ClinicalOncology (ASCO) meeting, to put new findings into the contextof existing therapies, Dr. Pazdur said. He expects between 50and 100 physicians to attend the conference.

Recent Videos
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
Related Content